1. If I have reported a financial relationship with an ineligible company, I understand that this information will be reviewed to determine whether this relationship precludes my participation, and I may be asked to provide additional information.
2. I will update my disclosure information should anything change.
3. Failure/Refusal to disclose, false disclosure, or inability to mitigate COI will disqualify me from participating in this activity.
4. I will support my presentation and clinical recommendations with the best available evidence from current medical literature. All scientific research referred to, reported or used in support or justification of patient care recommendations will conform to the generally accepted standards of experimental design, data collection and analysis.
5. I will give a balanced view of ALL therapeutic options and use generic names when discussing pharmaceutical products.
6. I will not advocate for or promote practices that are not, or not yet, adequately based on current science, evidence and clinical reasoning.
7. I will disclose unlabeled use of a product or an investigational use of a product not yet approved by the FDA.
8. I have not nor will I accept any honorarium/special payments from ineligible companies for my participation in this activity.
9. I will not promote or sell products (e.g. books) or services that serve my professional or financial interests during my presentation.